Lanean...
Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID‐19 pandemic
Tofacitinib is a Janus Kinase 3 inhibitor that is used in the treatment of alopecia areata. We recommended our alopecia areata patients to discontinue their tofacitinib treatment during the COVID‐19 pandemic for an average of 80 days. We aimed to evaluate the drug use and the SARS‐CoV‐2 infection st...
Gorde:
| Argitaratua izan da: | Dermatol Ther |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley & Sons, Inc.
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7883269/ https://ncbi.nlm.nih.gov/pubmed/33405372 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.14746 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|